Omega Diagnostics First Half Revenue Down Following Reduced Operations
Morningstar In April, Omega completed a strategic review, resulting in decision to focus on its Visitect CD4 advanced disease teast, as well as its allergy and food intolerance businesses, reducing its cost base significantly. In line with this, Omega sold off its ... |
from india intolerance - Google News https://ift.tt/2Qd8YNz
Comments
Post a Comment